904 Alvarado Road


Developer of human recombinant decorin core protein as a topical anti-scarring therapy designed to treat Dystrophic Epidermolysis Bullosa, a devastating , genetic, skin blistering disease. The company’s therapy is developing a gel formulation of human recombinant Decorin, an engineered form of the natural anti-scarring protein, that binds collagen and facilitates the proper development, maintenance, and repair of structural components of the extracellular matrix, enabling patients to promote healthy tissue regeneration and reduce excessive scarring.